Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.61 |
| ▸ | CA2 | P00918 | 7/20 | 0.61 |
| ▸ | CA9 | Q16790 | 7/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629806 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL13294871 | 0.86 | KMT2A (0.61) | KMT2AALDH1A1LMNARXFP1MAPK1 | |
| SCHEMBL28417802 | 0.86 | KMT2A (0.61) | KMT2AALDH1A1LMNARXFP1MAPK1 | |
| SCHEMBL4241317 | 0.85 | KMT2A (0.60) | KMT2AALDH1A1LMNARXFP1MAPK1 | |
| SCHEMBL12916670 | 0.85 | KMT2A (0.60) | KMT2AALDH1A1LMNARXFP1MAPK1 | |
| SCHEMBL1553581 | 0.85 | KMT2A (0.63) | KMT2AALDH1A1LMNARXFP1MAPK1 | |
| SCHEMBL10891943 | 0.84 | KMT2A (0.58) | KMT2AALDH1A1LMNARXFP1MAPK1 | |
| SCHEMBL6112823 | 0.84 | CA2 (0.55) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL1186312 | 0.82 | CA2 (0.54) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL11323083 | 0.81 | KMT2A (0.56) | KMT2AALDH1A1LMNARXFP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177391-A1 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4482825-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | President and Fellows of Harvard College (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023196714-A9 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023196714-A9 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023196714-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196714-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-12 | — | — | WO | disclosed |
| US-4414152-A | Bis aryl-azo derivatives of 2,3-naphthalenediol | EASTMAN KODAK COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
| US-4414320-A | Bis aryl-azo derivatives of 2,3-naphthalenediol and electrophotographic liquid developer compositions containing them | EASTMAN KODAK COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177391-A1 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | DDR2, DDR1, DDRGK1 | CA1 4865/4885CA2 4361/4885CA9 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.